Wall Street rises as investors watch stimulus, pandemic and earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
BMO Capital Reiterates Market Perform Rating on Facebook (FB) Ahead of 2Q
July 27, 2020 7:00 AM EDTBMO Capital analyst Daniel Salmon reiterated a Market Perform rating and $220.00 price target on Facebook (NASDAQ: FB) ahead of the company's 2Q earnings report. Salmon expects near-term trends to be among the strongest in BMO Capital's ad supported coverage universe and continues to believe boycotts... More
Moderna (MRNA) Initiates Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)
July 27, 2020 6:53 AM EDTModerna, Inc., (NASDAQ: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against COVID-19 has begun dosing participants. The Phase 3 study, called the COVE (Coronavirus Efficacy) study, is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant... More
